<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Times" color="#000000"/>
	<fontspec id="font1" size="10" family="Times,Italic" color="#000000"/>
	<fontspec id="font2" size="7" family="Times,Italic" color="#000000"/>
	<fontspec id="font3" size="9" family="Times,Italic" color="#000000"/>
	<fontspec id="font4" size="6" family="Times,Italic" color="#000000"/>
	<fontspec id="font5" size="12" family="Helvetica,Bold" color="#ffffff"/>
	<fontspec id="font6" size="10" family="Times" color="#000000"/>
	<fontspec id="font7" size="7" family="Times" color="#000000"/>
	<fontspec id="font8" size="10" family="Symbol" color="#000000"/>
	<fontspec id="font9" size="11" family="Times,Bold" color="#000000"/>
<text top="42" left="257" width="98" height="8" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">NCIC CTG MAP.3 TRIAL</text>
<text top="765" left="226" width="161" height="9" font="font1" id="p1_t2" reading_order_no="117" segment_no="15" tag_type="text">C URRENT O NCOLOGY — V OLUME 14, N UMBER 3<i>C</i></text>
<text top="755" left="61" width="13" height="11" font="font5" id="p1_t3" reading_order_no="116" segment_no="13" tag_type="text">92<i>URRENT</i></text>
<text top="84" left="55" width="239" height="9" font="font6" id="p1_t4" reading_order_no="1" segment_no="2" tag_type="text">committee decided to halt the trial and revise the<i> O</i></text>
<text top="95" left="55" width="41" height="9" font="font6" id="p1_t5" reading_order_no="2" segment_no="2" tag_type="text">protocol.<i>NCOLOGY</i></text>
<text top="105" left="73" width="221" height="9" font="font6" id="p1_t6" reading_order_no="3" segment_no="3" tag_type="text">The revised MAP .3 study now compares exemes-<i>—</i></text>
<text top="117" left="55" width="239" height="9" font="font6" id="p1_t7" reading_order_no="4" segment_no="3" tag_type="text">tane to placebo in a 1:1 ratio in 4560 postmenopausal<i>V</i></text>
<text top="128" left="55" width="239" height="9" font="font6" id="p1_t8" reading_order_no="5" segment_no="3" tag_type="text">women who are 35 years of age or older and at in-<i>OLUME</i></text>
<text top="138" left="55" width="239" height="9" font="font6" id="p1_t9" reading_order_no="6" segment_no="3" tag_type="text">creased risk for the development of breast cancer. For<i> 14, N</i></text>
<text top="150" left="55" width="239" height="9" font="font6" id="p1_t10" reading_order_no="7" segment_no="3" tag_type="text">the purposes of this protocol, “increased risk” is de-<i>UMBER</i></text>
<text top="161" left="55" width="239" height="9" font="font6" id="p1_t11" reading_order_no="8" segment_no="3" tag_type="text">fined as being over the age of 60, or having a Gail<i> 3</i></text>
<text top="171" left="55" width="239" height="9" font="font6" id="p1_t12" reading_order_no="9" segment_no="3" tag_type="text">score greater than 1.65, or having a prior atypical<b>92</b></text>
<text top="183" left="55" width="239" height="9" font="font6" id="p1_t13" reading_order_no="10" segment_no="3" tag_type="text">breast biopsy (atypical ductal hyperplasia, atypical</text>
<text top="194" left="55" width="239" height="9" font="font6" id="p1_t14" reading_order_no="11" segment_no="3" tag_type="text">lobular hyperplasia, or lobular carcinoma in situ), or</text>
<text top="204" left="55" width="239" height="9" font="font6" id="p1_t15" reading_order_no="12" segment_no="3" tag_type="text">having a prior diagnosis of DCIS that was treated with</text>
<text top="216" left="55" width="239" height="9" font="font6" id="p1_t16" reading_order_no="13" segment_no="3" tag_type="text">a mastectomy. Women are stratified on their Gail</text>
<text top="223" left="55" width="239" height="13" font="font6" id="p1_t17" reading_order_no="14" segment_no="3" tag_type="text">score ( ≤ 2 vs. &gt;2) and current low-dose (&lt;100 mg</text>
<text top="237" left="55" width="239" height="9" font="font6" id="p1_t18" reading_order_no="15" segment_no="3" tag_type="text">daily) aspirin use (yes vs. no) before being randomly</text>
<text top="249" left="55" width="201" height="9" font="font6" id="p1_t19" reading_order_no="16" segment_no="3" tag_type="text">allocated to the treatment or placebo group.</text>
<text top="270" left="55" width="116" height="9" font="font9" id="p1_t20" reading_order_no="17" segment_no="5" tag_type="title">4.2 Rationale for Placebo</text>
<text top="293" left="55" width="239" height="9" font="font6" id="p1_t21" reading_order_no="18" segment_no="6" tag_type="text">Despite the fact that tamoxifen has been approved as</text>
<text top="303" left="55" width="239" height="9" font="font6" id="p1_t22" reading_order_no="19" segment_no="6" tag_type="text">a means to reduce breast cancer risk in women who</text>
<text top="315" left="55" width="239" height="9" font="font6" id="p1_t23" reading_order_no="20" segment_no="6" tag_type="text">would be eligible for this trial, it was decided that the</text>
<text top="326" left="55" width="239" height="9" font="font6" id="p1_t24" reading_order_no="21" segment_no="6" tag_type="text">use of a placebo control arm was justified for several</text>
<text top="336" left="55" width="38" height="9" font="font6" id="p1_t25" reading_order_no="22" segment_no="6" tag_type="text">reasons:<i>in situ</i>), or</text>
<text top="359" left="55" width="4" height="9" font="font6" id="p1_t26" reading_order_no="23" segment_no="9" tag_type="list">•</text>
<text top="359" left="73" width="221" height="9" font="font6" id="p1_t27" reading_order_no="24" segment_no="9" tag_type="list">Although tamoxifen is approved for the indica-</text>
<text top="369" left="73" width="221" height="9" font="font6" id="p1_t28" reading_order_no="25" segment_no="9" tag_type="list">tion of reducing the short-term incidence of breast</text>
<text top="381" left="73" width="221" height="9" font="font6" id="p1_t29" reading_order_no="26" segment_no="9" tag_type="list">cancer, many women whose level of risk would</text>
<text top="392" left="73" width="221" height="9" font="font6" id="p1_t30" reading_order_no="27" segment_no="9" tag_type="list">qualify them for the prescription of tamoxifen</text>
<text top="401" left="73" width="221" height="10" font="font6" id="p1_t31" reading_order_no="28" segment_no="9" tag_type="list">refuse the drug because of its toxicity profile 52–55 .</text>
<text top="414" left="73" width="221" height="9" font="font6" id="p1_t32" reading_order_no="29" segment_no="9" tag_type="list">Raloxifene is another option that women may con-</text>
<text top="425" left="73" width="221" height="9" font="font6" id="p1_t33" reading_order_no="30" segment_no="9" tag_type="list">sider for breast cancer risk reduction, although it</text>
<text top="435" left="73" width="221" height="9" font="font6" id="p1_t34" reading_order_no="31" segment_no="9" tag_type="list">is not yet approved for that indication. However,</text>
<text top="447" left="73" width="221" height="9" font="font6" id="p1_t35" reading_order_no="32" segment_no="9" tag_type="list">although the risk profile for raloxifene may be<b>4.2 Rationale for Placebo</b></text>
<text top="458" left="73" width="221" height="9" font="font6" id="p1_t36" reading_order_no="33" segment_no="9" tag_type="list">better than that for tamoxifen, it is still associated</text>
<text top="468" left="73" width="221" height="9" font="font6" id="p1_t37" reading_order_no="34" segment_no="9" tag_type="list">with increased risk of thromboembolic events and</text>
<text top="478" left="73" width="221" height="11" font="font6" id="p1_t38" reading_order_no="35" segment_no="9" tag_type="list">decreased sexual function 27 . Therefore, there re-</text>
<text top="491" left="73" width="221" height="9" font="font6" id="p1_t39" reading_order_no="36" segment_no="9" tag_type="list">mains a population of women eligible for this trial</text>
<text top="501" left="73" width="221" height="9" font="font6" id="p1_t40" reading_order_no="37" segment_no="9" tag_type="list">who have chosen or will choose, even after ap-</text>
<text top="513" left="73" width="221" height="9" font="font6" id="p1_t41" reading_order_no="38" segment_no="9" tag_type="list">propriate counselling, to avoid taking tamoxifen</text>
<text top="524" left="73" width="221" height="9" font="font6" id="p1_t42" reading_order_no="39" segment_no="9" tag_type="list">or raloxifene. These women may well wish to enter</text>
<text top="534" left="73" width="221" height="9" font="font6" id="p1_t43" reading_order_no="40" segment_no="9" tag_type="list">a placebo-controlled trial where the agents under</text>
<text top="546" left="73" width="221" height="9" font="font6" id="p1_t44" reading_order_no="41" segment_no="9" tag_type="list">study may have more favourable toxicity profiles.</text>
<text top="557" left="55" width="4" height="9" font="font6" id="p1_t45" reading_order_no="42" segment_no="11" tag_type="list">•</text>
<text top="557" left="73" width="221" height="9" font="font6" id="p1_t46" reading_order_no="43" segment_no="11" tag_type="list">The ASCO Technology Assessment of Pharmaco-</text>
<text top="567" left="73" width="221" height="9" font="font6" id="p1_t47" reading_order_no="44" segment_no="11" tag_type="list">logic Interventions for Breast Cancer Risk Re-</text>
<text top="579" left="73" width="221" height="9" font="font6" id="p1_t48" reading_order_no="45" segment_no="11" tag_type="list">duction Including Tamoxifen, Raloxifene and</text>
<text top="588" left="73" width="221" height="11" font="font6" id="p1_t49" reading_order_no="46" segment_no="11" tag_type="list">Aromatase Inhibition 56 concluded that “placebo</text>
<text top="600" left="73" width="221" height="9" font="font6" id="p1_t50" reading_order_no="47" segment_no="11" tag_type="list">controls are appropriate for breast cancer risk re-</text>
<text top="612" left="73" width="221" height="9" font="font6" id="p1_t51" reading_order_no="48" segment_no="11" tag_type="list">duction trials since no intervention has been dem-</text>
<text top="623" left="73" width="221" height="9" font="font6" id="p1_t52" reading_order_no="49" segment_no="11" tag_type="list">onstrated to favorably impact net health or</text>
<text top="633" left="73" width="221" height="9" font="font6" id="p1_t53" reading_order_no="50" segment_no="11" tag_type="list">survival.” Although the MAP .3 trial is not expected</text>
<text top="645" left="73" width="221" height="9" font="font6" id="p1_t54" reading_order_no="51" segment_no="11" tag_type="list">to demonstrate an impact on survival, the results</text>
<text top="656" left="73" width="221" height="9" font="font6" id="p1_t55" reading_order_no="52" segment_no="11" tag_type="list">may well indicate a more favourable therapeutic</text>
<text top="666" left="73" width="221" height="9" font="font6" id="p1_t56" reading_order_no="53" segment_no="11" tag_type="list">ratio for exemestane than for tamoxifen or</text>
<text top="678" left="73" width="49" height="9" font="font6" id="p1_t57" reading_order_no="54" segment_no="11" tag_type="list">raloxifene.</text>
<text top="689" left="55" width="4" height="9" font="font6" id="p1_t58" reading_order_no="55" segment_no="14" tag_type="list">•</text>
<text top="689" left="73" width="221" height="9" font="font6" id="p1_t59" reading_order_no="56" segment_no="14" tag_type="list">The placebo arm will allow for a true determina-</text>
<text top="699" left="73" width="221" height="9" font="font6" id="p1_t60" reading_order_no="57" segment_no="14" tag_type="list">tion of efficacy in reducing invasive breast can-</text>
<text top="711" left="73" width="221" height="9" font="font6" id="p1_t61" reading_order_no="58" segment_no="14" tag_type="list">cer, of adverse effects, and of impact on overall</text>
<text top="722" left="73" width="182" height="9" font="font6" id="p1_t62" reading_order_no="59" segment_no="14" tag_type="list">and menopausal-specific quality of life.</text>
<text top="83" left="318" width="98" height="9" font="font9" id="p1_t63" reading_order_no="60" segment_no="1" tag_type="title">4.3 Study Procedures</text>
<text top="105" left="318" width="238" height="9" font="font6" id="p1_t64" reading_order_no="61" segment_no="4" tag_type="text">Women enrolled in the MAP .3 research study will have</text>
<text top="117" left="318" width="239" height="9" font="font6" id="p1_t65" reading_order_no="62" segment_no="4" tag_type="text">a bone-mineral density test and a mammogram be-</text>
<text top="128" left="318" width="239" height="9" font="font6" id="p1_t66" reading_order_no="63" segment_no="4" tag_type="text">fore being randomized. Women can be enrolled at</text>
<text top="138" left="318" width="239" height="9" font="font6" id="p1_t67" reading_order_no="64" segment_no="4" tag_type="text">centres in Canada, the United States, or Spain. Par-</text>
<text top="150" left="318" width="239" height="9" font="font6" id="p1_t68" reading_order_no="65" segment_no="4" tag_type="text">ticipants will be asked to return to their local study</text>
<text top="161" left="318" width="239" height="9" font="font6" id="p1_t69" reading_order_no="66" segment_no="4" tag_type="text">centre twice during the first year, at 6 and 12 months,</text>
<text top="171" left="318" width="239" height="9" font="font6" id="p1_t70" reading_order_no="67" segment_no="4" tag_type="text">and then annually for follow-up visits for the remain-</text>
<text top="183" left="318" width="239" height="9" font="font6" id="p1_t71" reading_order_no="68" segment_no="4" tag_type="text">ing 4 years of the study. At each visit, participants</text>
<text top="194" left="318" width="239" height="9" font="font6" id="p1_t72" reading_order_no="69" segment_no="4" tag_type="text">will be given a new supply of the study medications</text>
<text top="204" left="318" width="239" height="9" font="font6" id="p1_t73" reading_order_no="70" segment_no="4" tag_type="text">and will be asked to answer questions about their</text>
<text top="216" left="318" width="239" height="9" font="font6" id="p1_t74" reading_order_no="71" segment_no="4" tag_type="text">quality of life and about any illnesses or discomfort</text>
<text top="227" left="318" width="239" height="9" font="font6" id="p1_t75" reading_order_no="72" segment_no="4" tag_type="text">they may have experienced since their last visit. At</text>
<text top="237" left="318" width="239" height="9" font="font6" id="p1_t76" reading_order_no="73" segment_no="4" tag_type="text">each annual visit, participants will undergo a physi-</text>
<text top="249" left="318" width="239" height="9" font="font6" id="p1_t77" reading_order_no="74" segment_no="4" tag_type="text">cal and health exam and a mammogram. At three dif-</text>
<text top="260" left="318" width="239" height="9" font="font6" id="p1_t78" reading_order_no="75" segment_no="4" tag_type="text">ferent times during the study, serum samples will also</text>
<text top="270" left="318" width="239" height="9" font="font6" id="p1_t79" reading_order_no="76" segment_no="4" tag_type="text">be taken for hormone testing. If additional consent</text>
<text top="282" left="318" width="239" height="9" font="font6" id="p1_t80" reading_order_no="77" segment_no="4" tag_type="text">has been given for DNA testing, a blood sample taken</text>
<text top="293" left="318" width="234" height="9" font="font6" id="p1_t81" reading_order_no="78" segment_no="4" tag_type="text">at baseline will be stored for future genetic testing.</text>
<text top="314" left="318" width="145" height="9" font="font9" id="p1_t82" reading_order_no="79" segment_no="7" tag_type="title">4.4 Study Goals and Population</text>
<text top="336" left="318" width="238" height="9" font="font6" id="p1_t83" reading_order_no="80" segment_no="8" tag_type="text">The main objective of the MAP .3 trial is to compare</text>
<text top="348" left="318" width="239" height="9" font="font6" id="p1_t84" reading_order_no="81" segment_no="8" tag_type="text">the incidence of breast cancer in the two treatment</text>
<text top="359" left="318" width="239" height="9" font="font6" id="p1_t85" reading_order_no="82" segment_no="8" tag_type="text">groups. Information will also be recorded and com-</text>
<text top="369" left="318" width="239" height="9" font="font6" id="p1_t86" reading_order_no="83" segment_no="8" tag_type="text">pared between treatment groups on clinical bone frac-</text>
<text top="381" left="318" width="239" height="9" font="font6" id="p1_t87" reading_order_no="84" segment_no="8" tag_type="text">tures, cardiovascular events, quality of life, tolerability</text>
<text top="392" left="318" width="239" height="9" font="font6" id="p1_t88" reading_order_no="85" segment_no="8" tag_type="text">and safety, and incidences of other malignancies. A<b>4.3 Study Procedures</b></text>
<text top="402" left="318" width="239" height="9" font="font6" id="p1_t89" reading_order_no="86" segment_no="8" tag_type="text">companion study to evaluate the long-term effects of</text>
<text top="414" left="318" width="239" height="9" font="font6" id="p1_t90" reading_order_no="87" segment_no="8" tag_type="text">exemestane on bone density and bone biomarkers is</text>
<text top="425" left="318" width="189" height="9" font="font6" id="p1_t91" reading_order_no="88" segment_no="8" tag_type="text">planned for a subset of participating sites.</text>
<text top="435" left="336" width="221" height="9" font="font6" id="p1_t92" reading_order_no="89" segment_no="10" tag_type="text">Some of the biggest challenges of conducting a</text>
<text top="447" left="318" width="239" height="9" font="font6" id="p1_t93" reading_order_no="90" segment_no="10" tag_type="text">breast cancer prevention trial include recruiting</text>
<text top="458" left="318" width="239" height="9" font="font6" id="p1_t94" reading_order_no="91" segment_no="10" tag_type="text">women from the general population and defining the</text>
<text top="468" left="318" width="239" height="9" font="font6" id="p1_t95" reading_order_no="92" segment_no="10" tag_type="text">groups at high-risk for the development of breast</text>
<text top="480" left="318" width="239" height="9" font="font6" id="p1_t96" reading_order_no="93" segment_no="10" tag_type="text">cancer that are most eligible for chemoprevention.</text>
<text top="491" left="318" width="239" height="9" font="font6" id="p1_t97" reading_order_no="94" segment_no="10" tag_type="text">Well established cancer cooperative groups with af-</text>
<text top="501" left="318" width="239" height="9" font="font6" id="p1_t98" reading_order_no="95" segment_no="10" tag_type="text">filiated clinical research centers in North America,</text>
<text top="513" left="318" width="239" height="9" font="font6" id="p1_t99" reading_order_no="96" segment_no="10" tag_type="text">Europe, and Australia are available to help with re-</text>
<text top="524" left="318" width="239" height="9" font="font6" id="p1_t100" reading_order_no="97" segment_no="10" tag_type="text">cruitment of cancer patients into therapeutic trials.</text>
<text top="534" left="318" width="239" height="9" font="font6" id="p1_t101" reading_order_no="98" segment_no="10" tag_type="text">However, that model is not so easy to replicate for</text>
<text top="546" left="318" width="239" height="9" font="font6" id="p1_t102" reading_order_no="99" segment_no="10" tag_type="text">cancer prevention trials. The clinicians that typically</text>
<text top="557" left="318" width="239" height="9" font="font6" id="p1_t103" reading_order_no="100" segment_no="10" tag_type="text">see well women are more likely to be primary care</text>
<text top="567" left="318" width="239" height="9" font="font6" id="p1_t104" reading_order_no="101" segment_no="10" tag_type="text">physicians or other internal specialists such as gyne-</text>
<text top="579" left="318" width="239" height="9" font="font6" id="p1_t105" reading_order_no="102" segment_no="10" tag_type="text">cologists. However, primary care physicians in par-</text>
<text top="590" left="318" width="239" height="9" font="font6" id="p1_t106" reading_order_no="103" segment_no="10" tag_type="text">ticular do not appear to be comfortable prescribing</text>
<text top="599" left="318" width="239" height="10" font="font6" id="p1_t107" reading_order_no="104" segment_no="10" tag_type="text">chemoprevention medication 57–59 , and based on re-</text>
<text top="612" left="318" width="239" height="9" font="font6" id="p1_t108" reading_order_no="105" segment_no="10" tag_type="text">sults from a recent national survey in the United</text>
<text top="623" left="318" width="239" height="9" font="font6" id="p1_t109" reading_order_no="106" segment_no="10" tag_type="text">States, the decision to prescribe tamoxifen was greatly</text>
<text top="633" left="318" width="239" height="9" font="font6" id="p1_t110" reading_order_no="107" segment_no="10" tag_type="text">affected by logistics and the ability of the physician</text>
<text top="643" left="318" width="118" height="11" font="font6" id="p1_t111" reading_order_no="108" segment_no="10" tag_type="text">to determine eligibility 59 .<b>4.4 Study Goals and Population</b></text>
<text top="656" left="336" width="221" height="9" font="font6" id="p1_t112" reading_order_no="109" segment_no="12" tag_type="text">For the MAP .3 trial to be feasible, the NCIC CTG had</text>
<text top="666" left="318" width="239" height="9" font="font6" id="p1_t113" reading_order_no="110" segment_no="12" tag_type="text">to assemble a consortium of clinical researchers in</text>
<text top="678" left="318" width="239" height="9" font="font6" id="p1_t114" reading_order_no="111" segment_no="12" tag_type="text">Canada and the United States who were committed</text>
<text top="689" left="318" width="239" height="9" font="font6" id="p1_t115" reading_order_no="112" segment_no="12" tag_type="text">to cancer prevention research and who had partici-</text>
<text top="699" left="318" width="239" height="9" font="font6" id="p1_t116" reading_order_no="113" segment_no="12" tag_type="text">pated in earlier prevention trials with the Women’s</text>
<text top="711" left="318" width="239" height="9" font="font6" id="p1_t117" reading_order_no="114" segment_no="12" tag_type="text">Heath Initiative ( WHI ) or the National Surgical Adju-</text>
<text top="722" left="318" width="239" height="9" font="font6" id="p1_t118" reading_order_no="115" segment_no="12" tag_type="text">vant Breast and Bowel Project. Nonetheless, recruit-</text>
</page>
</pdf2xml>
